Global response aid reports midyear sales results for covid drug

Dubai, uae, june 3, 2021 /prnewswire/ -- healthcare solutions provider global response aid (gra) today reported seven-month global sales figures for its anti-viral tablet avigan®/reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of covid-19. "over the course of a year, gra has signed a global licensing agreement for avigan® with its developer, fujifilm toyama, filed a drug dossier with various regulators, and recently initiated a global phase 3 clinical trial in an outpatient setting," said gra ceo mitch wilson.
RDY Ratings Summary
RDY Quant Ranking